Intraoperative PEEP Optimization: Effects on Postoperative Pulmonary Complications and Inflammatory Response

Inflammatory Response Clinical Trial

Official title:

Intraoperative PEEP Optimization: Effects on Postoperative Pulmonary Complications and Inflammatory Response. A Double-center, Prospective, Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02931409
• Other study ID #: 21586-4/2016/EKU
• Secondary ID: CO-338-045149/20
• Status: Completed
• Phase: N/A
• Start date: October 2016
• Est. completion date: March 31, 2019

Study information

• Verified date: April 2019
• Source: Péterfy Sándor Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this prospective randomized controlled trial is to determine the effects of intraoperative lung protective mechanical ventilation using an individual optimal PEEP value on postoperative pulmonary complications and inflammatory response. A total number of 40 patients undergoing open radical cystectomy and urinary diversion will be enrolled and randomized into two groups. Standard lung protective ventilation using a PEEP of 6 cmH2O will be performed in control group and an optimal PEEP value determined during a static pulmonary compliance (Cstat) directed PEEP titration procedure will be applyed in study group. Low tidal volumes (6mL/Kg IBW) and a fraction of inspired oxygen (FiO2) of 0.5 will be applyed in both groups. Procalcitonin kinetics will be monitored during and after surgery until the third postoperative day as well as postoperative pulmonary complications. Clinical condition and extrapulmonary complications will be evaluated by the Sequential Organ Failure Assessment (SOFA) Score and in-hospital stay, 28-days and in-hospital mortality will also be followed.

Description:

Patients undergoing general anesthesia and mechanical ventilation during major abdominal surgery commonly develop pulmonary atelectasis or even hyperdistension of the lungs can occur leading to adverse consequences either intraoperatively or postoperatively. Lung protective ventilation (LPV, PEEP = 6 cmH2O, TV = 6 mL/Kg IBW and regular recruitments) during the intraoperative period can reduce the risk of ventilator induced lung injury (VILI) and prevent the formation of pulmonary atelectasis.

In our investigator-initiated, double-center, single-blinded, prospective, randomized, controlled clinical trial a total number of 40 patients with bladder cancer undergoing open radical cystectomy and urinary diversion (ileal conduit or orthotopic bladder substitute) will be enrolled and randomized into two groups. Standard lung protective mechanical ventilation with the use of 6 cmH2O of PEEP and low tidal volumes (6mL/Kg IBW), a fraction of inspired oxygen (FiO2) of 0.5 and a respiratory rate to maintain an end tidal carbon dioxide (ETCO2) between 35-40 mmHg will be performed in control group, and a strategy of lung protective mechanical ventilation applying an optimal, individual PEEP determined by static pulmonary compliance (Cstat) directed PEEP titration procedure will be performed in study group.

During preoperative assessment, respiratory failure risk index (RFRI) will be recorded and informed consent will be obtained. Regarding to the protocol, a central vein catheter will be placed on the day before surgery, serum procalcitonin (PCT) level will be measured and a chest X-ray examination will be performed.

Before induction of anesthesia, an epidural catheter and an arterial canula for invasive blood pressure monitoring will be inserted. Immediately after induction of anesthesia and orotracheal intubation, all patients will be submitted to an alveolar recruitment maneuver (ARM) using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds. After ARM PEEP will be set to 6 cmH2O in the control group ("standard PEEP") and LPV will be performed. In the study group ("optimal PEEP") PEEP will be set to 14 cmH2O and a Cstat directed decremental PEEP titration procedure will be performed (every 4 minutes PEEP will be decreased by 2 cmH2O, until a final PEEP of 6 cmH2O) to determine the best individual PEEP. During surgery ARM will be repeated and arterial and central vein blood gas samples (ABGs, CVBGs) will be evaluated every 60 minutes. PCT levels will be measured 2, 6, 12, 24, 48 and 72 hours after surgical incision.

After extubation, patients will be addmitted to the Department of Anesthesiology and Intensive Care. ABGs and CVBGs will be collected and evaluated, PaO2/FiO2 and dCO2 will be calculated every 6 hours until 72 hours after surgery. On the first postoperative day chest X-ray will be performed and repeated on the following days if developing of pulmonary complications were suspected. Continuous epidural analgesia will be introduced, and evaluated effective if numeric pain rating scale point would be lower than 3 points.

During postoperative care continuous intraabdominal pressure (IAP) monitoring via a direct intraperitoneal catheter placed before closure of the abdominal wall will be performed to eliminate bias caused by the elevation of intraabdominal pressure.

Patients' clinical progress and secondary endpoints will be monitored by daily SOFA Scores, laboratory and physical examinations.

During follow-up period in-hospital stay, 28-days and in-hospital mortality will also be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: March 31, 2019
• Est. primary completion date: March 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with bladder cancer undergoing radical cystectomy and urinary diversion (ileal conduit or orthotopic bladder substitute)

Exclusion Criteria:

• Age < 18 years

• ASA grade IV

• History of severe chronic obstructive pulmonary disease (COPD, GOLD grade III or IV)

• History of severe or uncontrolled bronchial asthma

• History of severe restrictive pulmonary disease

• Pulmonary metastases

• History of any thoracic surgery

• Need for thoracic drainage before surgery

• Renal replacement therapy prior to surgery

• Congestive heart failure (NYHA grade III or IV)

• Extreme obesity (BMI > 35 Kg/m2)

• Lack of patient's consent

Related Conditions & MeSH terms

• Inflammatory Response
• Pulmonary Complications

Intervention

Procedure:
• Optimal PEEP
Optimal PEEP determined by Cstat during PEEP titration procedure.
• Standard PEEP
Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O

Locations

Country	Name	City	State
Hungary	Péterfy Sándor Hospital	Budapest	Pest
Hungary	University of Szeged, Faculty of Medicine, Department of Anaesthesiology and Intensive Therapy	Szeged	Csongrád

Sponsors (2)

Lead Sponsor	Collaborator
Péterfy Sándor Hospital	Szeged University

Country where clinical trial is conducted

Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	ICU days	Defined as a period from the first postoperative day until emission from the ICU.	28 days
Other	In-hospital Stay	From the day of surgery until emission from hospital.	28 days
Other	Mortality	In-hospital and 28 days mortality.	28 days
Primary	Postoperative Pulmonary Complications	New infiltrates or atelectasis on chest X-ray, abnormal breathing sounds on auscultation, excessive bronchial secretions, unexplained fever, respiratory failure defined as PaO2/FiO2 < 300 or need for non-invasive or invasive ventilatory support.	72 hours
Primary	Procalcitonin Kinetics	Serum procalcitonin levels during and after surgery.	72 hours
Secondary	Incidence of Circulatory Failure	Severe hypotension, arrhytmias, decreased cardiac output, severe metabolic acidosis, congestive heart failure, acute coronary syndrome, pulmonary embolism and cardiac arrest.	28 days
Secondary	Incidence of Gastrointestinal Dysfunctions	Constipation or ileus, anastomotic leakage and need for urgent reoperation, disorders of liver function.	28 days
Secondary	Incidence of Renal Dysfunction	RIFLE Criteria	28 days
Secondary	Incidence of Hematologic and Coagulation Disorders	Severe bleeding and/or coagulopathy	72 hours
Secondary	Infection	Any infections except from pneumonia.	28 days